Barclays’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-33,116
| Closed | -$49.7K | – | 5294 |
|
|
2023
Q1 | $49.7K | Hold |
33,116
| – | – | ﹤0.01% | 4447 |
|
|
2022
Q4 | $33.1K | Sell |
33,116
-445
| -1% | -$600 | ﹤0.01% | 4689 |
|
|
2022
Q3 | $60K | Sell |
33,561
-1,964
| -6% | -$5.7K | ﹤0.01% | 3729 |
|
|
2022
Q2 | $103K | Sell |
35,525
-4,952
| -12% | -$12.2K | ﹤0.01% | 3751 |
|
|
2022
Q1 | $111K | Sell |
40,477
-8,594
| -18% | -$27K | ﹤0.01% | 3731 |
|
|
2021
Q4 | $229K | Buy |
49,071
+16,039
| +49% | +$100K | ﹤0.01% | 3516 |
|
|
2021
Q3 | $281K | Sell |
33,032
-9,203
| -22% | -$130K | ﹤0.01% | 3451 |
|
|
2021
Q2 | $694K | Sell |
42,235
-6,544
| -13% | -$132K | ﹤0.01% | 2886 |
|
|
2021
Q1 | $1.08M | Buy |
48,779
+37,344
| +327% | +$1.02M | ﹤0.01% | 2728 |
|
|
2020
Q4 | $353K | Sell |
11,435
-3,561
| -24% | -$90K | ﹤0.01% | 3457 |
|
|
2020
Q3 | $304K | Buy |
14,996
+6,027
| +67% | +$106K | ﹤0.01% | 3574 |
|
|
2020
Q2 | $138K | Buy |
8,969
+5,076
| +130% | +$58.5K | ﹤0.01% | 4324 |
|
|
2020
Q1 | $30K | Sell |
3,893
-7,992
| -67% | -$97.8K | ﹤0.01% | 5496 |
|
|
2019
Q4 | $169K | Buy |
11,885
+6,000
| +102% | +$92.8K | ﹤0.01% | 5158 |
|
|
2019
Q3 | $89K | Buy |
5,885
+4,713
| +402% | +$73.4K | ﹤0.01% | 5567 |
|
|
2019
Q2 | $16K | Sell |
1,172
-1,146
| -49% | -$18.3K | ﹤0.01% | 6469 |
|
|
2019
Q1 | $40K | Buy |
+2,318
| New | +$41.1K | ﹤0.01% | 6033 |
|
Barclays's TCRR Position: Q2 2023 in Review
Barclays sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 33,116 shares — an estimated $49.7K sold.
Barclays first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $1.08M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Barclays reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Barclays sold 33,116 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $49.7K.
- Barclays first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- Barclays's TCR2 Therapeutics Inc. Common Stock position peaked at $1.08M in Q1 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.